Advertisement


Leora Horn, MD, MSc, on Targeted and Emerging Therapies for Metastatic NSCLC

2015 NCCN Annual Conference

Advertisement

Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.



Related Videos

Robert W. Carlson, MD, and John A. Gentile, Jr, on Milestones of NCCN

Robert W. Carlson, MD, Chief Executive Officer, National Comprehensive Cancer Network, and John A. Gentile, Jr, Chairman, Harborside Press, LLC, discuss the early days of NCCN, controversies that surrounded the first meeting, oncologists’ embrace of the guidelines, and how the organization has evolved over the past 20 years.

Kidney Cancer

Eric Jonasch, MD, on Kidney Cancer: Current and Novel Treatment Options

Eric Jonasch, MD, of The University of Texas, MD Anderson Cancer Center, discusses the progress being made in kidney cancer treatment and the clinical trials that focused on sunitinib, sorafenib, and everolimus, among others.

Pancreatic Cancer
Hematologic Malignancies

Samuel M. Silver, MD, PhD, and Margaret A. Tempero, MD, on Multidisciplinary Management of Pancreatic Cancer

Samuel M. Silver, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and Margaret A. Tempero, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discuss drugs developed for hematologic malignancies that have activity in pancreatic cancer, vaccines, neoadjuvant treatment, and the need to focus on activated RAS.

Skin Cancer

Anthony J. Olszanski, RPh, MD, on Immunotherapy and Melanoma

Anthony J. Olszanski, RPh, MD, of the Fox Chase Cancer Center, discusses the advances in immunotherapy generally and for melanoma in particular.

Lymphoma

Andrew D. Zelenetz, MD, PhD, on Emerging Treatment Options for Lymphomas

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, talks about the revolution in lymphoma treatment, which started with rituximab and continues with obinutuzumab, ibrutinib, and others.

Advertisement

Advertisement




Advertisement